医学. 医学. 医学. 作为治疗目标的PPAR:逆心脏病学?
1Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. jplutzky@rics.bwh.harvard.edu
概括
炎症驱动动动脉硬化和心脏病发作通过脂质负载的巨细胞. 过氧体增殖器激活受体 (PPAR),特别是PPAR-delta,是这些炎症途径的关键调节者.
科学领域:
- 心血管生物学 心血管生物学
- 炎症研究 炎症研究
- 分子内分泌学分子内分泌学
背景情况:
- 动脉样硬化是心肌梗塞的主要原因,涉及炎症过程.
- 含脂质的巨细胞是动脉样硬化病变形成中的关键细胞组成部分.
- 核受体在调节细胞反应和新陈代谢方面发挥着重要作用.
研究的目的:
- 突出氧酶增殖器激活受体 (PPARs) 在调节炎症反应中的作用.
- 强调PPAR-delta在动脉样硬化背景下的特定功能.
- 提供关于PPAR和心血管疾病的当前理解的概述.
主要方法:
- 对PPARs和炎症通路的现有文献的审查.
- 对研究PPAR-delta在巨生物学中的功能进行分析.
- 综合与PPARs对动脉样硬化病变发展的影响相关的发现.
主要成果:
- PPAR核受体,特别是PPAR-delta,与控制炎症反应有关.
- PPAR-delta的激活可以调节动脉样硬化病变中的炎症环境.
- 准PPAR途径可能为动脉样硬化提供治疗策略.
结论:
- PPAR-delta在调节动脉样硬化相关的炎症方面发挥着至关重要的作用.
- 调节PPAR活性为预防心肌梗塞提供了潜在的治疗途径.
- 对PPAR信号的进一步研究对于心血管疾病管理是有必要的.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


